SCHEMBL1915320

SCHEMBL1915320

CNc1nc(-c2ccccc2-c2ccc(OCc3ccccc3)nc2)cs1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.43
BRD4 O60885 1/20 0.41
CREBBP Q92793 1/20 0.41
RAB9A P51151 3/20 0.40
MAPT P10636 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
NPC1 O15118 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
THRB P10828 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
SLC12A2 P55011 1/20 0.40
WNK1 Q9H4A3 1/20 0.40
PLAU P00749 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
ATP4A P20648 2/20 0.39
ATP4B P51164 2/20 0.39
TSHR P16473 1/20 0.39
CYP19A1 P11511 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1915580 0.87 CYP19A1 (0.49) ARRAB9AMAPTMEN1KMT2A
SCHEMBL1915039 0.85 AR (0.48) ARRAB9AMAPTMEN1KMT2A
SCHEMBL1915663 0.84 AR (0.43) ARRAB9AMAPTMEN1KMT2A
SCHEMBL1915546 0.79 FFAR2 (0.43) RAB9AMAPTMEN1KMT2ANPC1
SCHEMBL1914971 0.78 AR (0.51) ARRAB9AMAPTMEN1KMT2A
SCHEMBL1916768 0.77 AR (0.50) ARRAB9AMAPTMEN1KMT2A
SCHEMBL1915793 0.77 NPC1 (0.54) ARRAB9AMAPTMEN1KMT2A
SCHEMBL1915608 0.76 AR (0.56) ARRAB9AMAPTMEN1KMT2A
SCHEMBL1916798 0.76 CCNK (0.41) ARRAB9AMAPTMEN1KMT2A
SCHEMBL1915120 0.75 AR (0.48) ARRAB9AMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102245574-A Compounds, pharmaceutical compositions and methods for treating metabolic disorders EUROSCREEN SA 2011-11-16 CN disclosed
US-20110230477-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS EUROSCREEN S.A. (BE) 2011-09-22 US disclosed
EP-2364297-A1 Compounds, pharmaceutical composition and methods for use in treating metabolic disorders Euroscreen S.A. (BE) 2011-09-14 EP disclosed
WO-2011076734-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES EUROSCREEN S.A. (BE) 2011-06-30 WO disclosed
WO-2011076732-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS EUROSCREEN S.A. (BE) 2011-06-30 WO disclosed
WO-2010066682-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS EUROSCREEN S.A. (BE) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230477-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS CPT1A, LIPC, PC AR 2226/4885BRD4 2780/4885CREBBP 1980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.